Ebovir Biotechnologie Inc. is a Quebec-based biotech focused on the AI-driven research and development of RNA-based therapeutics, mRNA vaccines, and molecular diagnostics targeting infectious diseases and cancer. With our lead R&D platform, Ebo-Pulmo™, we are developing a novel stem-loop RNA innate immune activator designed to stimulate antiviral interferon pathways. In parallel, we are engineering lung-targeted lipid nanoparticles (LNPs) for precise RNA delivery to respiratory tissues.
Backed by a dedicated scientific team and proprietary patented technologies, Ebovir is committed to advancing RNA innovation in Quebec and beyond, through active collaboration with academic institutions, clinical centers, and industry partners.
Learn more about our therapeutic R&D
  • Exosomes can transfer molecules from one cell to another via membrane vesicle trafficking, thereby influencing the immune system.

  • Exosomes aretiny, membrane-bound extracellular vesicles (30-150 nm) that function as intercellular messengers, transporting proteins, lipids, and nucleic acids to influence recipient cell behavior, particularly in regenerative medicine and skin rejuvenation.
    Leveraging our proprietary patented technologies and rigorous scientific validation, we translate frontier life science research into accessible health aesthetics.

    Explore the EboScience Lab 

Based on Ebovir‘s patented ​Lipid-Nano-particles (LNP) Formulation​

Evaluating different drugs and nutrients to load into liposomes

Active-loaded Nanocarriers